The fatty acid synthase (FAS) is considered one of the most complex cellular machines. The team led by Holger Stark and Ashwin Chari of the Max Planck Institute for Biophysical Chemistry has now ...

The fatty acid synthase (FAS) is considered one of the most complex cellular machines. The team led by Holger Stark and Ashwin Chari of the Max Planck Institute for Biophysical Chemistry has now ...

Fatty acid synthase (FAS) is the key enzyme of de novo fatty acid synthesis and has been shown to be involved in carcinogenesis of numerous human malignancies, including breast, colorectal, and ...

The fatty acid synthase (FAS) is considered one of the most complex cellular machines. The team led by Holger Stark and Ashwin Chari of the Max Planck Institute for Biophysical Chemistry has now ...

Tridecanoic acid (C13) is a rare, odd-chain saturated fatty acid produced mainly by gut and rumen microbes, entering ...

Researchers developed an alternative fatty acid synthase (FAS) system in which enzymes from other organisms work with the native FAS in E. coli to improve the microbe’s capacity for chemical ...

Fatty acid synthase (FAS) is highly expressed in many human cancers, including lung cancers. Previous work has shown that blocking FAS activity by cerulenin, a natural antibiotic, or C75, a ...

Fatty acids are essential in all living organisms: to store energy, form membranes, and multiply. They are produced by a complex cellular machinery – the fatty acid synthase (FAS). A team of the ...

The cryo-electron microscopy map at 1.9 angstrom resolution allows to visualize many molecular details within the fatty acid synthase. The molecular fatty acid factory is depicted in a transparent ...

The company is also investigating BJT-188, a preclinical liver-targeted fatty acid synthase (FASN) inhibitor, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

SAN MATEO, Calif., April 22, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN ...

A fungus (C. neoformans) grown in three conditions: untreated, treated with a sub-lethal dose of the fatty acid synthase inhibitor NPD6433, and treated with a fluconazole.